|
| | PCI 34051 Basic information |
| | PCI 34051 Chemical Properties |
| density | 1.25 | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | insoluble in H2O; insoluble in EtOH; ≥14.8 mg/mL in DMSO | | form | Powder | | pka | 9.16±0.30(Predicted) |
| Hazard Codes | Xn | | Risk Statements | 22-36 | | Safety Statements | 26 |
| | PCI 34051 Usage And Synthesis |
| Uses | PCI-34051 is a potent, histone deacetylase 8 (HDAC8)-specific inhibitor. PCI-34051 induces caspase-dependent apoptosis in cell lines derived from T-cell lymphomas or leukemias. PCI-34051 did not affect other hematopoietic or solid tumor lines. PCI-34051 treatment has been shown to significantly reduce cholesterol accumulation in Niemann-Pick type C1 gene mutated human fibroblast. | | Definition | ChEBI: N-hydroxy-1-[(4-methoxyphenyl)methyl]-6-indolecarboxamide is an indolecarboxamide. | | Biological Activity | pci-34051 is a potent, specific inhibitor of histone deacetylase 8 (hdac8) with greater than 200-fold selectivity over the other hdac isoforms, such as 1, 2, 3, 6 and 10. it induces caspase dependent apoptosis in cell lines derived from t-cell lymphomas or leukemias, but not in other hematopoietic or solid tumor lines. pci-34051 does not cause detectable histone or tubulin acetylation and also does not inhibit growth or induce apoptosis in normal cells such as pbmcs or fibroblasts. although a phospholipase c-gamma1 (plcgamma1) defective line is resistant, cells defective in t-cell receptor signaling are still sensitive to pci-34051 induced apoptosis. | | storage | -20°C |
| | PCI 34051 Preparation Products And Raw materials |
|
